Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
Dr John Harris Outlines the Outcomes of Stopping Treatment With Ruxolitinib Cream for Vitiligo
March 18th 2023Similar to other therapies, approximately 40% of patients with vitiligo who stopped treatment with ruxolitinib cream relapsed, but they achieved repigmentation once treatment was reinitiated, explained John Harris, MD, PhD, FAAD, director of the Vitiligo Clinic and Research Center at UMass Chan Medical School.
Read More
Dr Eva Parker: Climate Change Has Been Impacting Skin Diseases for Years
March 17th 2023Many people often don’t connect the dots between climate change and its impact on skin health, but these effects have been happening for years, said Eva R. Parker, MD, associate professor of dermatology at Vanderbilt University Medical Center.
Read More
Dr Monica Li Highlights Advances in Microneedling
March 17th 2023At the American Academy of Dermatology annual meeting there will be multiple presentations on hot topics and the latest advances in microneedling, explained Monica Li, MD, clinical instructor, Department of Dermatology and Skin Science, University of British Columbia.
Read More
Dr John Harris: There Are a Lot of Reasons to Talk About Vitiligo at This Year’s AAD Meeting
March 14th 2023There is a lot to talk about in the vitiligo space at this year’s annual meeting of the American Academy of Dermatology (AAD), said John Harris, MD, PhD, FAAD, director of the Vitiligo Clinic and Research Center at UMass Chan Medical School.
Read More
Retinal Physicians Report Reservations Around Ophthalmology Biosimilars
February 20th 2023There are 2 ranibizumab biosimilars approved in the United States, and with more ranibizumab and the first aflibercept biosimilars on the horizon, gaps in knowledge among retinal physicians should be addressed.
Read More
BRVO, CRVO Need More Effective Long-term Therapies
February 12th 2023While the current therapies are effective for treating branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), they are inadequate for long-term treatment in clinical practice, according to an analysis of real-world data.
Read More
High-Dose Aflibercept in Wet AMD and DME Provides Therapeutic Benefits, No New Safety Signals
February 12th 2023Two studies looking at a higher dose of aflibercept found that an 8-mg dose can be maintained at longer dosing intervals with similar benefits and no additional safety signals compared with the 2-mg dose.
Read More
Anti-VEGF Therapy vs Gold Standard in Preterm Babies With ROP: Dr Darius Moshfeghi
February 11th 2023The BUTTERFLEYE trial sought to determine if aflibercept, an anti–vascular endothelial growth factor (anti-VEGF) therapy, was equivalent to laser photocoagulation, the gold standard to treat retinopathy of prematurity (ROP) in preterm babies.
Read More
Dr Charles Wykoff Highlights the Latest Data on the RGX-314 Gene Therapy for Wet AMD
February 11th 2023Patients with wet age-related macular degeneration (AMD) who are responsive to anti–vascular endothelial growth factor (anti-VEGF) therapy experienced visual gains with no additional injections in the 6 months after treatment with the gene therapy.
Read More
Home OCT: Providing More Personalized, Timely Treatment for Wet AMD
February 11th 2023Home optical coherence tomography (OCT) has shown there is a wide degree of heterogeneity in fluid dynamics and treatment response that may not be clear during regular office visits and scans. Presenters reviewed the latest data in home OCT to manage wet age-related macular degeneration (AMD).
Read More
Mitochondrial Stabilizing Drugs Have Potential to Reverse Vision Loss in Dry AMD
February 10th 2023A review of data on 2 mitochondrial membrane stabilizers—risuteganib and elamipretide—has highlighted the potential to not just slow disease progression but actually reverse vision loss in patients with intermediate dry age-related macular degeneration (AMD).
Read More
Effects of Pegcetacoplan to Slow Progression of GA Increase Over Time: Dr Eleonora Lad
February 10th 2023For patients with geographic atrophy (GA) taking pegcetacoplan, the drug’s effect to slow disease progression increases over time as patients take the drug, said Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.
Read More
Angiogenesis Meeting to Highlight Latest in Technology, Translational Research, Clinical Trials
February 8th 2023The Angiogenesis, Exudation, and Degeneration 2023 meeting will be held virtually with a program focused on understanding and treating neovascular, exudative, and degenerative diseases of the eye.
Read More
Dr Eleonora Lad Highlights the Importance of Upcoming Pegcetacoplan Results
February 8th 2023With no treatment options currently available for geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), pegcetacoplan could fill a huge unmet need, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.
Read More